GET DAILY SIGNALSImmunityBio (IBRX): Following Anktiva's Revenue Surge in a Volatile Biotech Setting
Key Takeaways
- ImmunityBio is a commercial-stage biotechnology company whose lead product, Anktiva, anchors both its revenue and its growth narrative.
- Net product revenue grew roughly 700% in 2025 to $113 million, with sequential quarterly growth continuing into 2026.
- Anktiva's regulatory footprint has expanded to 34 countries across five jurisdictions, extending beyond its original bladder cancer indication.
- Despite meaningful short-term volatility, the stock's net move over the past 30 days has been relatively modest.
- The company remains unprofitable and carries a stockholders' deficit, making cash position and future funding central watch items.
- For additional detail on valuation, results, and projections, explore the Price Targets, Earnings, and Forecast pages.
- To discover algorithmic strategies across the market, visit the Trending AI Robots page.
Market Snapshot for IBRX
Shares of IBRX have moved across a wide band over the past year, from about $1.83 to $11.00, which is typical for early commercial-stage biotechs. Recent trading has kept the price between the upper single digits and just over $10 as the market balances fast revenue gains against ongoing losses. Over the latest 30 days the net change has stayed relatively contained compared with the longer-term trend, even though daily swings remain noticeable. This suggests investors are weighing Anktiva's expansion potential against the execution risks that come with scaling toward profitability.
Business Overview and Competitive Position
ImmunityBio focuses on next-generation immunotherapies that engage both innate and adaptive immune responses. The core platform, Cancer BioShield, centers on Anktiva (nogapendekin alfa inbakicept), an IL-15 receptor superagonist designed to boost natural killer cells, cytotoxic T cells, and memory T cells.
In the United States, Anktiva is approved with BCG for adults with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. That remains the main commercial driver today. The company is also advancing label expansions into non-small cell lung cancer and other solid and liquid tumors, treating Anktiva more as a platform therapy. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Investors track IBRX closely because its performance is tied closely to one commercial asset and the pace of regulatory and adoption milestones.
Recent Developments
Key updates have influenced sentiment recently. Net product revenue reached about $44.2 million in the first quarter of 2026, up 168% year over year and 15% sequentially, followed by roughly $50.7 million in the second quarter, up 92% year over year. Sequential growth has continued since the commercial launch of Anktiva.
Regulatory progress has been swift. The European Commission granted conditional marketing authorization early in 2026, Saudi Arabia’s SFDA approved it conditionally for metastatic non-small cell lung cancer, and the United Arab Emirates issued authorizations covering both NMIBC and NSCLC. The FDA accepted a supplemental Biologics License Application for Anktiva in BCG-unresponsive NMIBC with papillary tumors without CIS, with a PDUFA target date of January 6, 2027. The pivotal BCG-naïve trial completed enrollment, and a supplemental filing is planned for 2026. Non-cash charges related to a convertible note and warrants continue to affect reported net losses.
2026 Outlook and Key Items to Monitor
Looking forward, several factors are likely to shape the investment case. Continued adoption of Anktiva by U.S. urologists and the speed of international rollouts in Europe and the Middle East will drive revenue. Regulatory decisions, including the January 2027 PDUFA date and the planned 2026 filing from the BCG-naïve trial, stand out as potential catalysts. Cost trends are also relevant: management has noted that cost of sales will rise as pre-launch inventory runs down and operating expenses will increase with commercialization and label-expansion work.
Balance-sheet considerations remain important. The company finished the first quarter of 2026 with roughly $381 million in cash and marketable securities, yet it reports a stockholders’ deficit and sizable liabilities from a related-party convertible note and revenue interest obligation. Management expects existing cash, product sales, and possible equity offerings to support operations for at least the next 12 months, while highlighting substantial doubt about long-term viability without further funding. These elements, more than near-term price moves, are likely to frame the debate around IBRX through the rest of 2026.
Exploring Algorithmic Strategies
From what I see, quantitative tools can add useful perspective on volatile names like this. I often review Tickeron’s AI Daily Buy/Sell Signals when assessing how rules-based approaches are handling similar biotech situations.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
IBRX's Stochastic Oscillator stays in oversold zone for 6 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +2.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where IBRX advanced for three days, in 209 of 241 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
IBRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 119 of 123 cases where IBRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Bearish Trend Analysis
The 10-day RSI Indicator for IBRX moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator moved out of overbought territory. In 19 of the 20 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IBRX as a result. In 84 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The Moving Average Convergence Divergence Histogram (MACD) for IBRX turned negative on October 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In 46 of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
IBRX moved below its 50-day moving average on October 22, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-8.739) is normal, around the industry mean (2.974). P/E Ratio (-9.084) is within average values for comparable stocks, (-0.899). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.903) among similar stocks. P/S Ratio (47.847) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. IBRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 61 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IBRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
What is an Operating Expense?
Can I Rollover My 401(k) into an IRA?
If I Want to Establish a SEP IRA, Do I Have to Establish One for All Owners of My Business?
If hedge funds are using AI for investing, why shouldn't you?
What insights can we gain from the wealth and success of the 10 richest people in the world?
General Information
a producer of cancer treatment products
Industry Biotechnology
Advertisement